Symbols

DNTH

Dianthus·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DNTH

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company that developing novel medicine to bring the curative power of stem cell transplant to patients

Industry

Pharmaceutical

Established Date

06/17/2015

Listing Date

06/21/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.magentatx.com

Security Type

Common stock

Office address

7 Times Square, 43rd Floor, New York, New York 10036

Business

Introduction

Dianthus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on June 17, 2015. The company is a clinical-stage biotechnology company that develops new drugs to bring the therapeutic capabilities of bone marrow transplantation to more patients. The company intends to become a fully integrated discovery, development and commercial company in the field of transplant medicine. The company believes that the product portfolio will provide significant commercial synergies. The company is developing products so that they can be used alone or in combination with each other. Therefore, the company's portfolio can be used in a manner appropriate to the patient's disease so that patients can receive more than one magenta therapy as part of their personal transplant journey.

Company Financials

EPS

DNTH has released its 2025 Q3 earnings. EPS was reported at -0.97, versus the expected -0.9, missing expectations. The chart below visualizes how DNTH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DNTH has released its 2025 Q3 earnings report, with revenue of 396.00K, reflecting a YoY change of -81.77%, and net profit of -36.77M, showing a YoY change of -46.04%. The Sankey diagram below clearly presents DNTH's revenue sources and cost distribution.